Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vicarious Surgical Inc. (RBOT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public surgical robotics and medical device developer. These filings offer detailed information on the Vicarious Surgical System, the company’s operating expenses, capital structure, governance and listing status.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Vicarious Surgical presents audited and interim financial statements, segment information for research and development, sales and marketing, and general and administrative activities, along with risk factors and management’s discussion of its development-stage business. Current reports on Form 8-K disclose material events such as registered direct offerings and private placements of common stock and warrants, at-the-market offering agreements, cash burn guidance, board and committee changes, and special meetings of stockholders to approve warrant exercises under New York Stock Exchange rules.
Filings also document listing and registration matters. For example, a Form 25 filed by the New York Stock Exchange relates to the removal from listing and registration of Vicarious Surgical’s publicly traded warrants, while separate 8-K items describe the NYSE’s notice to commence delisting proceedings for those warrants and the continued listing of the company’s Class A common stock under the symbol RBOT, subject to compliance with NYSE standards.
On Stock Titan, these documents are supplemented by AI-powered summaries that explain the key points of lengthy filings, such as complex financing terms, warrant structures, or at-the-market programs. Users can quickly see highlights from 10-K and 10-Q reports, understand the implications of Form 8-K events, and review proxy materials like definitive proxy statements (DEF 14A) that cover special meetings and stockholder proposals. The page also links to information about warrants, capital raises and other securities-related disclosures, helping investors and researchers analyze how Vicarious Surgical funds and governs the development of its single-port robotic surgery platform.
Vicarious Surgical Inc. remains pre-revenue and reported a six-month net loss of $28.6 million and a three-month net loss of $13.2 million. Total assets declined to $40.9 million from $67.7 million, driven by lower cash and short-term investments. Cash and cash equivalents were $3.9 million and short-term investments were $20.1 million, totaling $23.96 million at June 30, 2025.
Management disclosed that these funds are insufficient to support operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern and requiring pursuit of additional equity or debt financing. The company reduced operating expenses year-over-year (R&D, G&A and S&M), improving loss from operations by ~13% for the six-month comparison. The NYSE notified the company of non-compliance with market capitalization standards but accepted the company’s cure plan for the specified review period. A CEO appointment was announced as a subsequent event.
Vicarious Surgical Inc. furnished a Current Report announcing that it issued a press release with its results for the second quarter ended June 30, 2025 and providing a business update. The 8-K attaches that press release as Exhibit 99.1 and includes an Inline XBRL cover page file as Exhibit 104. The filing states the furnished materials are not "filed" for purposes of the Exchange Act and are not incorporated by reference elsewhere unless explicitly stated. The report does not include financial tables, numerical earnings or balance sheet figures within the filing itself; readers must consult the attached press release for detailed results.
Vicarious Surgical director Ahmad Fuad acquired a stock option on June 27, 2025 giving the right to purchase 8,003 Class A common shares at an exercise price of $7.61. The option is reported as directly beneficially owned and has an expiration date of June 26, 2035.
The filing states the shares underlying the option will vest on June 27, 2026 (or one day prior to the issuer's next annual meeting), subject to continued service. The Form 4 was executed by an attorney-in-fact on August 11, 2025. The disclosure shows a routine director option grant with defined exercise price, vesting schedule, and expiration; no sales or dispositions are reported here.
Khalifa Sammy, identified as a director, a 10% owner and Chief Technology Officer of Vicarious Surgical Inc. (RBOT), reported an equity award on 06/27/2025. The filing shows acquisition of 25,025 stock options with an exercise price of $7.61. The options vest in 48 equal monthly installments beginning on the one-month anniversary of the grant, tying vesting to continued service. The options appear to carry a term that ends on 06/26/2035, and the number of derivative securities beneficially owned following the transaction is 25,025. The form is signed by an attorney-in-fact on 08/11/2025.
Donald F. Tang, a director of Vicarious Surgical Inc. (ticker: RBOT), reported receipt of a stock option on 06/27/2025. The option covers 5,335 underlying shares of Class A common stock with an exercise price of $7.61. The filing states all shares underlying the option will vest on June 27, 2026 or one day prior to the issuer's next annual meeting, whichever is earlier, provided the reporting person remains in service through the vesting date. The Form 4 shows the report was signed by an attorney-in-fact, Erin Checka, on 08/11/2025.
Clark Randolph, identified as a director of Vicarious Surgical Inc. (RBOT), reported an acquisition on Form 4 dated 06/27/2025. The filing shows an acquisition of 8,003 stock options with an exercise (conversion) price of $7.61. The options are exercisable into 8,003 shares of Class A common stock and are reported as direct ownership following the transaction.
The filing states all shares underlying the option will vest on June 27, 2026 (or one day prior to the issuer's next annual meeting), subject to continued service, and lists an associated date of 06/26/2035 in the exercisable/expiration field. The form was signed by an attorney-in-fact on 08/11/2025.
Adam David Sachs, who serves as President and a director of Vicarious Surgical Inc. (RBOT) and is listed as a 10% owner, acquired a grant of stock options on 06/27/2025. The grant covers 38,675 options with an exercise (conversion) price of $7.61 and an expiration date shown as 06/26/2035. The filing reports the options are held directly by the reporting person following the acquisition.
The award vests in 48 equal monthly installments beginning one month after the grant date, subject to continued service through each vesting date. The Form 4 was signed and dated 08/11/2025 by an attorney-in-fact for the reporting person.
Vicarious Surgical director Beverly A. Huss was reported as receiving a stock option to purchase 5,335 shares of Class A common stock with an exercise price of $7.61. The award is a stock option (right to buy) that will vest on June 27, 2026, or one day prior to the issuer's next annual meeting of shareholders, whichever is earlier, subject to continued service. The option shows an expiration date in mid-2035 and the post-transaction beneficial position is 5,335 options held directly.
Vicarious Surgical director David D. Ho reported the grant of a stock option covering 5,335 shares of Class A common stock in a Form 4 filed for the issuer Vicarious Surgical Inc. (RBOT). The option has an exercise/conversion price of $7.61, a transaction date of 06/27/2025, and an expiration date of 06/26/2035. The filing shows the reporting person holds 5,335 shares underlying the option following the reported transaction, held in a direct ownership form.
The grant was reported by an attorney-in-fact, signed on 08/11/2025. Per the explanatory note, the option shares will vest on June 27, 2026 (or one day before the next annual meeting), subject to continued service. No earnings or other company financial data are included in this Form 4.
Reporting person listed as FROM STEPHEN, identified as Chief Executive Officer and a director, was granted 297,600 stock options on 08/07/2025 with an $8.92 exercise price. The award vests 25% on August 7, 2026, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service. The options convert into Class A common stock, are reported as a direct holding, and show an apparent expiration date of 08/06/2035. The grant ties executive pay to share performance and creates potential dilution if the options are exercised.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
